Sparsentan

Drug Profile

Sparsentan

Alternative Names: DARA - Pharmacopeia; DARA - Retrophin; PS-433540; RE-021

Latest Information Update: 13 Sep 2016

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Retrophin
  • Class Antihypertensives; Isoxazoles; Small molecules; Spiro compounds; Sulfonamides
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Focal segmental glomerulosclerosis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Focal segmental glomerulosclerosis
  • Discontinued Hypertension

Most Recent Events

  • 01 Mar 2017 Retrophin plans a phase III trial in Focal segmental glomerulosclerosis in USA
  • 13 Sep 2016 Interim adverse events data from a phase II/III trial in focal segmental glomerulosclerosis released by Retrophin
  • 07 Sep 2016 Interim efficacy data from a phase II/III trial in focal segmental glomerulosclerosis released by Retrophin
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top